By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sequenta, Inc. 

400 East Jamie Court
Suite 301
South San Francisco  California  94080  U.S.A.
Phone: 650-243-3900 Fax: 650-243-3897


Company News
Sequenta, Inc. Enters Agreement With Illumina, Inc. (ILMN) On In Vitro Diagnostic Kit For Sequencing-Based Minimal Residual Disease Testing 11/17/2014 7:12:52 AM
Celgene (CELG) Participates In New Round Of Investment For Sequenta, Inc. 10/20/2014 11:36:11 AM
Sequenta, Inc. And Collaborators To Share Clonosight MRD Data In Four Presentations At European Hematology Association 5/23/2014 6:46:40 AM
Study Shows Sequenta, Inc.’s Sequencing-Based Minimal Residual Disease (MRD) Detection Technology Has Prognostic Value In Multiple Myeloma 5/15/2014 8:41:34 AM
Sequenta, Inc. And Collaborators To Present Lymphoma And Immunotherapy Data At Annual Meeting Of The American Society of Clinical Oncology 5/15/2014 8:07:19 AM
Sequenta, Inc.’s Next-Generation Sequencing-Based Minimal Residual Disease (MRD) Quantification Technology Shown To Predict Post-Transplant Relapse And Survival In Adult Acute Lymphoblastic Leukemia (ALL) Patients 5/8/2014 12:46:45 PM
Sequenta, Inc.’s Clonosight Test To Be Used By The Dana-Farber Cancer Institute/Acute Lymphoblastic Leukemia (ALL) Consortium 2/25/2014 9:39:56 AM
Sequenta, Inc. Issued Third U.S. Patent, Augmenting Its Strong Intellectual Property Portfolio 2/18/2014 9:53:35 AM
Sequenta, Inc.'s ClonoSIGHT MRD Test Can Detect Relapse Of Diffuse Large B-Cell Lymphoma More Than Seven Months Before CT Scan 12/9/2013 10:07:27 AM
Sequenta, Inc.’s ClonoSIGHT Test Validated In Multiple Myeloma By Data To Be Presented At Annual Meeting Of The American Society of Hematology 12/9/2013 7:23:28 AM